Table 4. Results of proportional hazard Cox regression in 5 years OS and DFS among patients treated with neoadjuvant chemotherapy.
Survival | Stage | Survival No. (%) | Death No. (%) | Hazard ratio | 95% CI | p-value |
---|---|---|---|---|---|---|
OS | ||||||
Anatomic stage | IA | 291 (94.0) | 19 (6.0) | Reference | - | - |
IB | 40 (89.5) | 6 (10.5) | 1.8 | 0.7–4.5 | 0.2060 | |
IIA | 381 (93.1) | 29 (6.9) | 1.2 | 0.7–2.1 | 0.6290 | |
IIB | 205 (84.5) | 41 (15.5) | 2.7 | 1.6–4.7 | 0.0003 | |
IIIA | 151 (80.5) | 37 (19.5) | 3.5 | 2.0–6.1 | < 0.0001 | |
IIIB | 32 (68.8) | 15 (31.2) | 6.2 | 3.2–12.3 | < 0.0001 | |
IIIC | 111 (76.3) | 37 (23.7) | 4.5 | 2.6–7.8 | < 0.0001 | |
Clinical prognostic stage | IA | 219 (94.7) | 13 (5.3) | Reference | - | - |
IB | 269 (94.9) | 15 (5.1) | 0.9 | 0.5–2.0 | 0.9275 | |
IIA | 312 (93.6) | 22 (6.4) | 1.2 | 0.6–2.4 | 0.5875 | |
IIB | 153 (82.7) | 33 (17.3) | 3.4 | 1.8–6.5 | 0.0002 | |
IIIA | 96 (83.6) | 19 (16.4) | 3.2 | 1.6–6.6 | 0.0011 | |
IIIB | 132 (75.1) | 47 (24.9) | 5.2 | 2.8–9.7 | < 0.0001 | |
IIIC | 44 (56.3) | 35 (43.7) | 11.4 | 6.0–21.6 | < 0.0001 | |
DFS | ||||||
Anatomic stage | IA | 291 (94.3) | 18 (5.7) | Reference | - | - |
IB | 45 (89.5) | 6 (10.5) | 1.9 | 0.8–4.8 | 0.1703 | |
IIA | 381 (93.1) | 29 (6.9) | 1.2 | 0.7–2.2 | 0.5120 | |
IIB | 214 (84.5) | 41 (15.5) | 2.9 | 1.7–5.0 | 0.0002 | |
IIIA | 151 (81.0) | 36 (19.0) | 3.6 | 2.1–6.4 | < 0.0001 | |
IIIB | 32 (68.8) | 15 (31.2) | 6.6 | 3.3–13.1 | < 0.0001 | |
IIIC | 111 (76.3) | 37 (23.7) | 4.8 | 2.7–8.3 | < 0.0001 | |
Clinical prognostic stage | IA | 219 (94.7) | 13 (5.3) | Reference | - | - |
IB | 269 (95.2) | 14 (4.8) | 0.9 | 0.4–1.9 | 0.7882 | |
IIA | 312 (93.6) | 22 (6.4) | 1.2 | 0.6–2.4 | 0.5874 | |
IIB | 153 (82.7) | 33 (17.3) | 3.4 | 1.8–6.5 | 0.0002 | |
IIIA | 96 (84.4) | 18 (15.6) | 3.1 | 1.5–6.3 | 0.0021 | |
IIIB | 132 (75.1) | 47 (24.9) | 5.2 | 2.8–9.7 | < 0.0001 | |
IIIC | 44 (56.3) | 35 (43.7) | 11.5 | 6.1–21.7 | < 0.0001 |
OS=overall survival; DFS=disease-free survival; CI=confidence interval.